LONDON – Midatech Pharma Ltd. is preparing for an initial public offering (IPO) in which it will raise £30 million (US$47 million) to fund phase I development of its gold nanoparticle needle-free insulin delivery system and the expansion of its technology into the targeted delivery of chemotherapy drugs.